MedPath

Luteal Supplementation With Rec-LH After GnRH-agonist Triggering in In Vitro (IVF)

Phase 4
Conditions
Pregnancy
Pregnancy Loss
Interventions
Drug: 300IU rec-LH
Registration Number
NCT00954811
Lead Sponsor
Universitair Ziekenhuis Brussel
Brief Summary

Our aim is to access whether we can achieve equivalent pregnancy rates by the addition of six doses of luteal support with recLH after agonist triggering for IVF cycles in the absence of OHSS.

Detailed Description

Whether pregnancy outcome after GnRH-agonist triggering could be improved by adding luteal recLH support plus progesterone, compared to that observed after ovulation triggering with HCG in GnRH antagonist stimulated cycles.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
40
Inclusion Criteria
  • < 36years,
  • single blastocystET,
  • FSH < 12
Exclusion Criteria
  • endometriosis,
  • 3 and 4,
  • pco,
  • frozen sperm

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
HCG for ovulation triggering and luteal progesteroneprogesterone 600mgconventional triggering with HCG and conventional luteal support with progesterone
Agonist triggering and rec-LH luteal support plus progesterone300IU rec-LHnew method of triggering with GnRH-agonist and proof of concept intervention with novel way of luteal support with rec-LH plus the usual co-treatment with progesterone
Primary Outcome Measures
NameTimeMethod
pregnancy occurrence, pregnancy loss14 days after OPU
Secondary Outcome Measures
NameTimeMethod
hormone levels, OHSS, endometrium14 days after oocyte pick up

Trial Locations

Locations (1)

Centre for Reproductive Medicine, UZ Brussel

🇧🇪

Brussels, Jette, Belgium

© Copyright 2025. All Rights Reserved by MedPath